We are using a precision medicine approach to discover and develop innovative therapies designed to inhibit abnormally functioning cellular pathways that drive cancer growth. Our lead candidate drug: Tipifarnib, is being explored in treatment of patients with selected types of cancer, including HRAS Mutant Squamous Head and Neck Cancers.